These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 16767876)

  • 21. Mixed incontinence.
    Wein AJ
    J Urol; 2005 Jun; 173(6):2055-7. PubMed ID: 15879826
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability.
    Kilic N; Balkan E; Akgoz S; Sen N; Dogruyol H
    Int J Urol; 2006 Feb; 13(2):105-8. PubMed ID: 16563131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Editorial comment on: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Speakman MJ
    Eur Urol; 2009 Sep; 56(3):542-3. PubMed ID: 19070420
    [No Abstract]   [Full Text] [Related]  

  • 24. Editorial comment on: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Dmochowski R
    Eur Urol; 2009 Sep; 56(3):542. PubMed ID: 19070419
    [No Abstract]   [Full Text] [Related]  

  • 25. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
    Abrams P; Kaplan S; De Koning Gans HJ; Millard R
    J Urol; 2006 Mar; 175(3 Pt 1):999-1004; discussion 1004. PubMed ID: 16469601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tolterodine for the treatment of overactive bladder: a review.
    Rovner ES
    Expert Opin Pharmacother; 2005 Apr; 6(4):653-66. PubMed ID: 15934891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medical treatment of overactive bladder.
    Rackley R; Wein A; Nelson D
    Mayo Clin Proc; 2001 Nov; 76(11):1179-80. PubMed ID: 11702910
    [No Abstract]   [Full Text] [Related]  

  • 28. The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder.
    Dmochowski R; Kreder K; MacDiarmid S; Carlsson M; Guan Z
    BJU Int; 2007 Jul; 100(1):107-10. PubMed ID: 17552957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urinary incontinence management: new questions from old assumptions.
    DuBeau CE
    J Am Geriatr Soc; 2001 Jun; 49(6):829-30. PubMed ID: 11454125
    [No Abstract]   [Full Text] [Related]  

  • 30. [A drug seeks its disease].
    Löfgren O
    Lakartidningen; 2010 Jun 2-8; 107(22):1488-9. PubMed ID: 20645604
    [No Abstract]   [Full Text] [Related]  

  • 31. Review. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine.
    Kobelt G; Kirchberger I; Malone-Lee J
    BJU Int; 1999 Apr; 83(6):583-90. PubMed ID: 10233562
    [No Abstract]   [Full Text] [Related]  

  • 32. A meta-analysis comparing trials of antimuscarinic medications funded by industry or not.
    Tulikangas PK; Ayers A; O'Sullivan DM
    BJU Int; 2006 Aug; 98(2):377-80. PubMed ID: 16879680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tolterodine for overactive bladder.
    Med Lett Drugs Ther; 1998 Oct; 40(1038):101-2. PubMed ID: 9813595
    [No Abstract]   [Full Text] [Related]  

  • 34. Modern pharmacotherapy of urge urinary incontinence in the USA: tolterodine and oxybutynin.
    Rovner ES; Wein AJ
    BJU Int; 2000 Oct; 86 Suppl 2():44-53; discussion 53-4. PubMed ID: 11501617
    [No Abstract]   [Full Text] [Related]  

  • 35. Effectiveness of tolterodine in nonneurogenic voiding dysfunction.
    Babu R
    Indian Pediatr; 2006 Nov; 43(11):980-3. PubMed ID: 17151401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medication update.
    Slagle M
    South Med J; 2002 Feb; 95(2):188-91. PubMed ID: 11846243
    [No Abstract]   [Full Text] [Related]  

  • 37. Syndrome of inappropriate antidiuretic hormone associated with tolterodine therapy.
    Bryan MK; Nguyen MT; Hilas O
    Consult Pharm; 2010 May; 25(5):320-2. PubMed ID: 20497930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anticholinergic drugs for overactive bladder.
    Kripke C
    Am Fam Physician; 2006 Jan; 73(1):66. PubMed ID: 16417066
    [No Abstract]   [Full Text] [Related]  

  • 39. Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment.
    Bunyavejchevin S
    J Med Assoc Thai; 2005 Nov; 88(11):1497-501. PubMed ID: 16471092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Editorial comment.
    de Jong TP
    J Urol; 2009 Oct; 182(4 Suppl):2038; discussion 2039. PubMed ID: 19695627
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.